6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 01 Jul 2024
- Reporting date
- 01 Jul 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
GSK plc reports
- Company location
- London
GSK plc has filed 6,797 SEC EDGAR filings since 12 Jan 2001
SEC filing history
Showing 626-650 of 1,000 matching filings.
Per page
25
Current page
26
6-K
File 001-15170
STATEMENT: ZANTAC (RANITIDINE) LITIGATION
- Filing date
- 28 Jun 2024
- Reporting date
- 28 Jun 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
EMA VALIDATES JEMPERLI MARKETING AUTHORISATION
- Filing date
- 24 Jun 2024
- Reporting date
- 24 Jun 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
OMJJARA APPROVED IN JAPAN FOR MYELOFIBROSIS
- Filing date
- 24 Jun 2024
- Reporting date
- 24 Jun 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 21 Jun 2024
- Reporting date
- 21 Jun 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
11-K
File 001-15170
ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE
- Filing date
- 18 Jun 2024
- Reporting date
- 31 Dec 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
11-K
File 001-15170
ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE
- Filing date
- 18 Jun 2024
- Reporting date
- 31 Dec 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 12 Jun 2024
- Reporting date
- 12 Jun 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
STATEMENT: ZANTAC (RANITIDINE) LITIGATION
- Filing date
- 11 Jun 2024
- Reporting date
- 11 Jun 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
STATEMENT: ZANTAC (RANITIDINE) LITIGATION
- Filing date
- 10 Jun 2024
- Reporting date
- 10 Jun 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
FDA APPROVES AREXVY FOR ADULTS 50-59 AT RISK
- Filing date
- 10 Jun 2024
- Reporting date
- 10 Jun 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
25-NSE
File 001-15170
25-NSE filing
- Filing date
- 03 Jun 2024
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 03 Jun 2024
- Reporting date
- 03 Jun 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
UNPRECEDENTED RESULTS IN JEMPERLI TRIAL CONTINUE
- Filing date
- 03 Jun 2024
- Reporting date
- 03 Jun 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
ASCO POSITIVE BLENREP DREAMM-8 TRIAL RESULTS
- Filing date
- 03 Jun 2024
- Reporting date
- 03 Jun 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
STATEMENT: ZANTAC (RANITIDINE) LITIGATION
- Filing date
- 03 Jun 2024
- Reporting date
- 03 Jun 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SD
File 001-15170
SPECIALIZED DISCLOSURE REPORT
- Filing date
- 31 May 2024
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
STATEMENT: ZANTAC (RANITIDINE) LITIGATION
- Filing date
- 24 May 2024
- Reporting date
- 24 May 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
POSITIVE PHASE III ASTHMA RESULTS FOR DEPEMOKIMAB
- Filing date
- 21 May 2024
- Reporting date
- 21 May 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 20 May 2024
- Reporting date
- 20 May 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
CURRENT REPORT
- Filing date
- 17 May 2024
- Reporting date
- 17 May 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK COMPLETES SALE OF SHARES IN HALEON PLC
- Filing date
- 17 May 2024
- Reporting date
- 17 May 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 14 May 2024
- Reporting date
- 14 May 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
BLOCK LISTING INTERIM REVIEW
- Filing date
- 13 May 2024
- Reporting date
- 13 May 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
RESULT OF AGM
- Filing date
- 08 May 2024
- Reporting date
- 08 May 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing